Seres Financial Statements From 2010 to 2024

MCRB Stock  USD 0.91  0.04  4.21%   
Seres Therapeutics financial statements provide useful quarterly and yearly information to potential Seres Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Seres Therapeutics financial statements helps investors assess Seres Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Seres Therapeutics' valuation are summarized below:
Gross Profit
-165.8 M
Profit Margin
(0.65)
Market Capitalization
143.7 M
Enterprise Value Revenue
1.4632
Revenue
126.8 M
We have found one hundred twenty available fundamental trend indicators for Seres Therapeutics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Seres Therapeutics current market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. As of May 22, 2024, Market Cap is expected to decline to about 170.2 M. In addition to that, Enterprise Value is expected to decline to about 251.9 M

Seres Therapeutics Total Revenue

132.64 Million

Check Seres Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Seres main balance sheet or income statement drivers, such as Depreciation And Amortization of 15.9 M, Interest Expense of 13.8 M or Selling General Administrative of 92.1 M, as well as many exotic indicators such as Price To Sales Ratio of 1.35, Dividend Yield of 0.0 or Days Sales Outstanding of 39.22. Seres financial statements analysis is a perfect complement when working with Seres Therapeutics Valuation or Volatility modules.
  
This module can also supplement Seres Therapeutics' financial leverage analysis and stock options assessment as well as various Seres Therapeutics Technical models . Check out the analysis of Seres Therapeutics Correlation against competitors.
For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.

Seres Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets225.8 M358.6 M180.1 M
Slightly volatile
Other Current Liabilities84.6 M80.6 M22 M
Slightly volatile
Total Current Liabilities103.6 M98.7 M38.9 M
Slightly volatile
Property Plant And Equipment Net138.9 M132.2 M40 M
Slightly volatile
Accounts Payable6.7 M3.6 M5.3 M
Slightly volatile
Cash93.9 M128 M75.4 M
Slightly volatile
Non Current Assets Total192.3 M183.2 M55.8 M
Slightly volatile
Other Assets24.2 M23.1 M10.1 M
Slightly volatile
Cash And Short Term Investments156.3 M128 M124.9 M
Slightly volatile
Common Stock Shares Outstanding134.4 M128 M57.7 M
Slightly volatile
Other Current Assets8.6 M9.1 M6.9 M
Slightly volatile
Total Liabilities423.6 M403.5 M156.3 M
Slightly volatile
Total Current Assets166.7 M175.4 M133.2 M
Slightly volatile
Common Stock141.8 K135 K56.6 K
Slightly volatile
Short and Long Term Debt Total224.6 M213.9 M52 M
Slightly volatile
Other Liabilities78 M108 M59.7 M
Slightly volatile
Current Deferred Revenue13.6 M7.7 M10 M
Slightly volatile
Common Stock Total Equity150.9 K143.8 K57.8 K
Slightly volatile
Liabilities And Stockholders Equity245.7 M358.6 M180.6 M
Slightly volatile
Non Current Liabilities Total320 M304.8 M119.8 M
Slightly volatile
Other Stockholder Equity497.1 M933.2 M364.6 M
Slightly volatile
Property Plant And Equipment Gross192.6 M183.4 M47 M
Slightly volatile
Short Term Debt6.4 M6.7 M4.9 M
Slightly volatile
Property Plant Equipment21.7 M26.4 M16.4 M
Slightly volatile
Short and Long Term Debt562.7 K410.4 K707.3 K
Slightly volatile
Capital Surpluse552.2 MB467.6 M
Slightly volatile
Non Current Liabilities Other1.5 M1.6 M57.3 M
Slightly volatile
Capital Lease Obligations118 M112.4 M32.1 M
Slightly volatile
Net Working Capital134.8 M76.8 M123.8 M
Very volatile
Capital Stock101.6 K135 K65.6 K
Slightly volatile
Long Term Debt Total34.2 M58.2 M29.3 M
Slightly volatile

Seres Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization15.9 M15.1 M4.1 M
Slightly volatile
Selling General Administrative92.1 M87.7 M33.9 M
Slightly volatile
Other Operating Expenses125.5 M233.6 M100 M
Slightly volatile
Research Development87.5 M145.9 M69.7 M
Slightly volatile
Total Operating Expenses124.1 M218.5 M98.9 M
Slightly volatile
Cost Of Revenue14.4 M15.1 M37.5 M
Pretty Stable
Interest Income7.1 M6.7 MM
Slightly volatile
Non Operating Income Net Other1.6 M2.7 M1.3 M
Slightly volatile
Reconciled Depreciation5.5 M6.2 MM
Slightly volatile
Non Recurring1.2 M1.3 M1.5 M
Slightly volatile

Seres Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation35.8 M34.1 M13 M
Slightly volatile
Begin Period Cash Flow82.9 M163 M65.9 M
Slightly volatile
Depreciation15.9 M15.1 M5.2 M
Slightly volatile
Capital Expenditures5.8 MM4.6 M
Slightly volatile
Total Cash From Financing Activities79.4 M71.7 M64.3 M
Slightly volatile
End Period Cash Flow95.4 M128 M76.6 M
Slightly volatile
Change To Netincome16.2 M29.3 M12.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.351.418620.2418
Very volatile
Days Sales Outstanding39.2222.5626.9253
Slightly volatile
Stock Based Compensation To Revenue0.260.26990.7304
Very volatile
EV To Sales1.992.099218.6642
Pretty Stable
Payables Turnover3.944.151113.0499
Slightly volatile
Sales General And Administrative To Revenue0.660.69461.824
Pretty Stable
Research And Ddevelopement To Revenue1.11.15464.3394
Pretty Stable
Cash Per Share0.950.99972.388
Very volatile
Days Payables Outstanding83.5387.9294643
Slightly volatile
Current Ratio1.691.777911.9527
Slightly volatile
Receivables Turnover13.7316.7517.0967
Slightly volatile
Graham Number2.512.64675.5325
Very volatile
Revenue Per Share0.570.98690.636
Pretty Stable
Interest Debt Per Share1.00.94840.457
Slightly volatile
Debt To Assets0.170.30180.2296
Pretty Stable
Days Of Payables Outstanding83.5387.9294643
Slightly volatile
Ebt Per Ebit1.111.06011.0232
Pretty Stable
Quick Ratio1.321.38511.7815
Slightly volatile
Net Income Per E B T0.770.910.9162
Very volatile
Cash Ratio1.231.29710.0646
Slightly volatile
Days Of Sales Outstanding39.2222.5626.9253
Slightly volatile
Fixed Asset Turnover1.020.95520.9915
Slightly volatile
Debt Ratio0.170.30180.2296
Pretty Stable
Price Sales Ratio1.351.418620.2418
Very volatile
Asset Turnover0.370.35230.1648
Slightly volatile

Seres Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap170.2 M179.2 M754.1 M
Slightly volatile
Enterprise Value251.9 M265.2 M714.7 M
Slightly volatile

Seres Fundamental Market Drivers

Cash And Short Term Investments128 M

Seres Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Seres Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Seres Therapeutics income statement, its balance sheet, and the statement of cash flows. Seres Therapeutics investors use historical funamental indicators, such as Seres Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Seres Therapeutics investors may use each financial statement separately, they are all related. The changes in Seres Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Seres Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Seres Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Seres Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue7.7 M13.6 M
Total Revenue126.3 M132.6 M
Cost Of Revenue15.1 M14.4 M
Stock Based Compensation To Revenue 0.27  0.26 
Sales General And Administrative To Revenue 0.69  0.66 
Research And Ddevelopement To Revenue 1.15  1.10 
Capex To Revenue(0.06)(0.07)
Revenue Per Share 0.99  0.57 
Ebit Per Revenue(0.85)(0.89)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:
Check out the analysis of Seres Therapeutics Correlation against competitors.
For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Seres Stock analysis

When running Seres Therapeutics' price analysis, check to measure Seres Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seres Therapeutics is operating at the current time. Most of Seres Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seres Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seres Therapeutics' price. Additionally, you may evaluate how the addition of Seres Therapeutics to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Is Seres Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.59)
Revenue Per Share
0.953
Quarterly Revenue Growth
(0.93)
Return On Assets
(0.16)
Return On Equity
(5.39)
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.